MSU researchers are hopeful that this new insight about cholesterol crystals in the retina could provide an opportunity for earlier diagnosis and treatment of diabetic retinopathy.
Diabetes and other metabolic disorders can lead to a buildup of cholesterol in the retina, which can contribute diabetic retinopathy, according to research done by investigators at Michigan State University (MSU). Diabetic retinopathy affects the blood vessels in the retina and can cause vision loss and blindness.
Cholesterol buildup can lead to the development of crystal deposits, and patients with diabetes are at risk for developing these crystals, researchers wrote in a paper published in the journal Diabetologia. This is the first study to demonstrate the presence of cholesterol crystals in diabetic retinopathy.
Julia V. Busik, Ph.D.
“Retinopathy is the leading cause of preventable blindness and one of the most feared complications of type 1 and type 2 diabetes,” Julia V. Busik, Ph.D., MSU professor emeritus of physiology and one of the study's authors, said in a press release. “Within 20 years of developing diabetes, every individual with either type 1 or type 2 diabetes will have some degree of retinopathy. Current treatment approaches are very invasive and are only directed at the very late stage of retinopathy.”
The cholesterol crystals in the retina are similar to the atherosclerotic plaques that can form in arteries and cause heart attacks. George Abela, chief of the MSU division of Cardiology, has identified ways to scan retinas using modified tissue preparation for scanning electron microscopy (SEM). This also helps researchers analyze the composition of the crystals.
MSU researchers are hopeful that this new insight could provide an opportunity for earlier diagnosis and treatment of diabetic retinopathy. Crystalized deposits, they said, are reflective and can be seen in images of the retina.
Researchers aimed to identify cholesterol crystals human diabetic retina, as well as pig and mouse retinal tissue. They found that cholesterol crystals were able to be identified in all cell cultures.
In the human samples, scanning electron microscope was used to identify the crystals. SEM is a microscope that uses electrons instead of light to form an image. Diabetic retinopathy was confirmed by medical records and with optical coherence tomography (OCT) imaging, which uses light waves to take a cross-section picture of the retina.
Researchers also performed an analysis of the element structure of the crystals to confirm that they were cholesterol based. Results were confirmed in both the diabetic mouse model and prediabetic pig model.
Although this study confirms the link between cholesterol and diabetic retinopathy, researchers said that additional studies are needed to show the role cholesterol crystals play in the development of diabetic retinopathy, as well as a potential treatment targeting the crystals.
In the mouse tissue, treatment with alpha cyclodextrin was able to remove the cholesterol crystals. Alpha cyclodextrin is a fiber from corn starch that can to bind to triglycerides.
The study was funded by the National Eye Institute and included contributions from researchers at the University of Alabama at Birmingham, Case Western Reserve University and Western University of Health Sciences.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Positive Long-term Results Seen with Vabysmo in Retinal Vein Occlusion
October 10th 2023The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More